Internal Medicine, Endocrinology, Diabetes, & Metabolism · Fountain Valley, CA
NPI
1316177462
Since 2009
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
16055 Brookhurst St, Suite #c
Fountain Valley, CA, 92708
Phone (714) 839-2400
Groups this clinician bills Medicare through
Medicare paid, 2024
$215K
3,577 services
Medicare patients, 2024
881
Average age 74
Drug cost, 2024
$8.2M
14,195 prescriptions
Company payments, 2025
$1,617
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Phong H Bui was code 99214 (office e&m - established), 1,370 times for 736 patients. In total Phong H Bui billed 3,577 services in 12 codes, and Medicare paid $215K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-07-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,370 | 736 | $99.85 | $137K |
| 82962 Clinical Chemistry | Office | 1,191 | 567 | $3.21 | $3,823 |
| 95251 Test - Miscellaneous | Office | 418 | 192 | $28.53 | $12K |
| 99215 Office E&M - Established | Office | 225 | 97 | $145.39 | $33K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 163 | 89 | $49.93 | $8,138 |
| 99204 Office E&M - New | Office | 141 | 141 | $130.45 | $18K |
| 96372 Injection Administration | Office | 27 | 15 | $11.16 | $301 |
| 99213 Office E&M - Established | Office | 24 | 16 | $54.14 | $1,299 |
By year: 2022 $184K for 2,802 services; 2023 $212K for 3,414 services; 2024 $215K for 3,577 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 1,191 | 567 | $3.21 | $3,823 |
Medicare prescription drug claims, 2024
In 2024, the drug Phong H Bui prescribed most often to Medicare patients was Ozempic (Semaglutide), with 1,314 prescriptions and refills. In total Phong H Bui wrote 14,195 Medicare prescriptions that cost $8.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 1,314 | 1,978 | 230 | $1.9M |
| Synjardy Xr Empagliflozin/Metformin Hcl | 1,141 | 1,927 | 214 | $1.1M |
| Jardiance Empagliflozin | 975 | 1,650 | 198 | $962K |
| Pioglitazone Hcl Generic | 820 | 1,762 | 205 | $7,124 |
| Trulicity Dulaglutide | 808 | 1,131 | 131 | $1.1M |
| Metformin Hcl Generic | 739 | 1,748 | 193 | $4,500 |
| Levothyroxine Sodium Generic | 700 | 1,718 | 177 | $7,351 |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 472 | 915 | 131 | $47K |
| Farxiga Dapagliflozin Propanediol | 455 | 824 | 103 | $448K |
| Rybelsus Semaglutide | 431 | 687 | 87 | $633K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 365 | 884 | 129 | $39K |
| Tresiba Flextouch U-100 Insulin Degludec | 362 | 867 | 95 | $107K |
| Rosuvastatin Calcium Generic | 349 | 873 | 92 | $4,120 |
| Alcohol Prep Pads Alcohol Antiseptic Pads | 334 | 720 | 133 | $2,864 |
| Atorvastatin Calcium Generic | 282 | 574 | 65 | $1,430 |
Brand drugs: 8,584 claims; generic drugs: 3,681 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Phong H Bui $1,617 ($1,617 in general payments such as food, travel and fees) from 18 companies. The largest payer was Novo Nordisk Inc with $310.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 15 | $310 |
| Amgen Inc. AMGN | 12 | $221 |
| Lilly USA, LLC LLY | 11 | $209 |
| Corcept Therapeutics CORT | 7 | $198 |
| Mannkind Corporation MNKD | 8 | $161 |
| Abbott Laboratories ABT | 4 | $100 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $90.43 |
| Dexcom, Inc. DXCM | 3 | $78.92 |
| Tandem Diabetes Care, Inc. TNDM | 3 | $48.64 |
| Alvogen Inc | 1 | $28.85 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.